12885_2019_5681_MOESM9_ESM.tif (65.77 MB)
Additional file 9: of Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
figure
posted on 2019-06-17, 05:00 authored by Noah Berlow, Rishi Rikhi, Mathew Geltzeiler, Jinu Abraham, Matthew Svalina, Lara Davis, Erin Wise, Maria Mancini, Jonathan Noujaim, Atiya Mansoor, Michael Quist, Kevin Matlock, Martin Goros, Brian Hernandez, Yee Doung, Khin Thway, Tomohide Tsukahara, Jun Nishio, Elaine Huang, Susan Airhart, Carol Bult, Regina Gandour-Edwards, Robert Maki, Robin Jones, Joel Michalek, Milan Milovancev, Souparno Ghosh, Ranadip Pal, Charles KellerFigure S9. Combination validation results for drug combinations SB-772077-B (GSK-PKA) + OSI-906. Results are based on n = 3 technical replicates with n = 4 replicates per treatment condition. (A) Dose response curve for OSI-906 varied dosage + SB-772077-B fixed dosage. Response for SB-772077-B at varied dosages is included. (B) Dose response curve for OSI-906 varied dosage + SB-772077-B low fixed dosage. (C) Dose response curve for SB-772077-B varied dosage + OSI-906 fixed dosage. The response for OSI-906 at varied dosages is included. (D) Dose response curve for SB-772077-B varied dosage + OSI-906 low fixed dosage. The response for OSI-906 at varied dosages is included. (TIF 67346 kb)
